If you own or track PACCAR (PCAR), the latest news from Washington might have caught your attention. President Trump’s administration just announced a sweeping 25% tariff on imported heavy-duty trucks, aiming to bolster American manufacturers such as PACCAR’s Peterbilt and Kenworth brands. As traders digested the impact, PACCAR’s shares jumped, reflecting optimism that a tougher stance on foreign competition could give the company some fresh tailwinds.

This tariff news arrives at a time when PACCAR’s share price has seen moderate momentum over the past year, climbing 6.7%. In recent months, however, there has been some fluctuation, with a 4.5% dip during the past month reversing on renewed tariff optimism, and a broader 5.9% gain over the most recent quarter. Investors have also kept an eye on the company’s capital allocation and growth efforts, including digital transformation investments and steady dividends. All of these factors contribute to how the market is weighing future earnings potential.

Following Friday’s price increase, the key question is whether PACCAR is now undervalued with extra room to grow or if investors have already priced the growth story into its stock price.

According to the most widely-followed narrative, PACCAR currently appears to be slightly undervalued based on analysts' projections of future earnings and market conditions. Consensus expectations suggest the business could benefit from several strategic and regulatory tailwinds, supporting a modest upside in share price over the coming years.

\\"Demand for new trucks is likely to rise meaningfully as customers pre-buy ahead of the 2027 NOx and greenhouse gas emissions standards. These standards will increase truck costs and incentivize earlier fleet upgrades, serving as a catalyst for revenue and earnings acceleration.\\"

Can PACCAR really ride this regulatory wave to unlock new growth? The story hinges on ambitious forecasts for its next phase, with future margins and profits set to climb if their biggest drivers line up. Wondering which bold industry shifts and financial bets analysts believe will power this target? The full narrative spells out the crucial steps and numbers behind their fair value calculation.

Result: Fair Value of $103.5 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing tariff changes and weaker truck demand in key regions could limit PACCAR's earnings growth and challenge current analyst expectations.

Find out about the key risks to this PACCAR narrative.

While analysts’ targets reflect growth potential, our DCF model offers a different perspective. It suggests PACCAR could be trading above its fair value. Could future cash flows trend lower than consensus expects?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out PACCAR for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

If you think there’s more to the story or want to dig into the numbers yourself, crafting a personal view takes just a few minutes. Do it your way

A great starting point for your PACCAR research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Great returns often involve identifying significant trends ahead of the majority. To ensure you discover all the opportunities, consider these proven themes that are shaping tomorrow’s market leaders.

Unlock hidden value by scanning for undervalued stocks based on cash flows that may be trading below their real potential. These opportunities could outperform as the market adjusts.

Explore the future of healthcare by targeting healthcare AI stocks that combine artificial intelligence with life sciences, supporting advancements in diagnostics, drug discovery, and patient care.

Stay ahead by tracking cryptocurrency and blockchain stocks leading the way in blockchain innovation and the evolving landscape of digital finance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PCAR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com